ISPOR Europe 2026

Workshop · AI · Hall F2, Level 0

Applied Generative AI for HEOR: Introduction

Sven L Klijn, Bristol Myers Squibb · William Rawlinson, Estima Scientific · Timothy Reason, Estima Scientific

Workshop · Real-World Evidence (RWE) · Hall E1, Level 0

Developing Decision-Grade Real-World Evidence

Jeremy Rassen, Arpeggio Solutions · Jennifer Polinski, CSL Behring

Workshop · AI · Hall E2, Level 0

Health Economic Modeling in R for Decision Making: Assessment, Adaptation, and AI-Assisted Validation

Howard Thom · Eline Krijkamp, Erasmus School of Health Policy and Management · Baris Deniz

Workshop · AI · Hall N1, Level 1

Prompt Engineering for HEOR: Practical Skills and Use Cases for HEOR Professionals

Jag Chhatwal, Harvard Medical School / Massachusetts General Hospital · Dalia Dawoud, Cytel · Turgay Ayer, Value Analytics Labs

Workshop · Access and Pricing · Hall N2, Level 1

Risk-Sharing/Performance-Based Arrangements in Developing Countries

Bertalan Németh, Syreon Research Institute · Rok Hren, Syreon Research Institute · Katarzyna Kolasa, University of Gdansk; University of Utah, Gdansk; Salt Lake City, UT

Workshop · Access and Pricing · Hall F1, Level 0

Reimbursement Systems for Pharmaceuticals in Europe

Mondher Toumi, Aix-Marseille University · Frank-Ulrich Fricke, Technische Hochschule Nürnberg · Keith H Tolley, Tolley Limited · Krzysztof Kloc, Clever-Access · Oriol INNOVATION TECHNOLOGY TRANSFER Solà-Morales Serra · Claudio Jommi, Universita del Piemonte Orientale

Workshop · AI · Hall F2, Level 0

Applied Generative AI for HEOR: Robust Architectures

Sven L Klijn, Bristol Myers Squibb · Rajdeep Kaur, Pharmacoevidence Pvt. Ltd. · Ghayath Janoudi, Loon, Ottawa

Workshop · Real-World Evidence (RWE) · Hall E1, Level 0

Causal Inference and Causal Estimands from Target Trial Emulations Using Evidence from Real-World Observational Studies and Clinical Trials

Uwe Siebert, UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health · Felicitas Kuhne, Pfizer Pharma GmbH · Nicholas Latimer, SCHARR, University of Sheffield

Workshop · Patient-Centered Evidence · Room 1.85-1.86, Level 1

Designing a Patient-Centered Strategy for Drug Development and Value

Ari Gnanasakthy, RTI Health Solutions · Lynda Doward, RTI Health Solutions · Shanshan Qin, RTI Health Solutions · Rebecca Crawford, RTI Health Solutions · Diane Whalley, RTI Health Solutions

Workshop · Expanded Value Measures · Hall N2, Level 1

Integrating Patient, Payer, and Investor Perspectives on Valuing Innovative Medicines for Orphan Diseases

Lou Garrison, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute · Marlene Gyldmark, BeiGene · Mark J Nuijten, A2M

Workshop · AI · Hall N1, Level 1

Practical Applications of Large Language Models for Real-World Evidence Generation and HEOR

Manuel Cossio, Cytel · Benjamin Bray, Lane Clark and Peacock

Keynote · Hall A, Level 2

Plenary Session 1: Opening Remarks and Special Address

Rob Abbott, ISPOR · Olivér Varhelyi, Health and Animal Welfare European Commission

Panel · Expanded Value Measures · Hall A, Level 2

Plenary Session 1: The Science of What Matters: Rethinking Value in Healthcare

Sandra Nestler-Parr, Biocryst Pharmaceuticals · Harald Schmidt, Maastricht University · Sally Lewis, Kintsugi International

Panel · Expanded Value Measures · Hall K2, Level -2

Beyond the Index Event: Aligning Hospital Decision-Making with Expanded Value Measures for Medical Devices and Diagnostics

Belinda A Mohr, Medtronic · Marjan Hummel, Philips · Sally Lewis, Kintsugi International · Abeer A Al Rabayah, King Hussein Cancer Center

Talk · Theater 2, Hall X1-X4, Level -2

Capturing Patient and Caregiver Experiences in Psychological and Cognitive Conditions

Irina Kinchin, Trinity College Dublin

Talk · Theater 1, Hall X1-X4, Level -2

Converting Vaccine Evidence to Policy

Tiberius Certejan, Merz Therapeutics

Workshop · Expanded Value Measures · Hall F2, Level 0

Early Value Assessment When There Are Multiple External Comparators: Introducing Value-Based Decision Boundary Analysis (VB-DBA)

Ronan Mahon, University of Galway · SUBHAJIT GUPTA, PHARMAQUANT INSIGHTS PVT LTD · Kokuvi ATSOU, Sanofi · Jonathan Salcedo, BioNTech SE

Panel · AI · Hall D, Level -2

Humans at the Helm: Navigating Increasing AI Autonomy in HEOR and HTA

Bill Malcolm, Bristol Myers Squibb · Dalia Dawoud, Cytel · J. Jaime Caro, Thermo Fisher Scientific · Siguroli Teitsson, Bristol Myers Squibb

Panel · Access and Pricing · Hall F1, Level 0

Navigating Europe’s New Era of Health Policy Reform: How Will the EU HTA Regulation, Pharmaceutical Legislation Revision, Critical Medicines Act, and Biotech Act Shape Medicines Development and Patient Access?

Suzette Matthijsse, Lumanity · Rui SANTOS IVO, European Medicines Agency · Anne Willemsen, Zorginstituut Nederland · Neil Grubert, Neil Grubert Consulting · Maya Matthews, European Commission

Panel · Patient-Centered Evidence · Hall E2, Level 0

Patient-Reported Outcomes in Federated Real-World Data: Infrastructure Ready, Evidence Fit for HTA?

Uwe Siebert, UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health · Katia Verhamme · Mario Lawes, Data4Life · Anke-Peggy Holtorf, Health Outcomes Strategies, GmbH

Panel · Hall G1, Level -2

The Historical Linear Life Science Model is Dead and Requires Rethinking to Adapt to a Rapidly Changing Ecosystem

Carole Longson, University of Manchester · Eric Low, Eric Low Consulting · Sean Tunis, Tufts Center for the Evaluation of Value and Risk in Health · Keith H Tolley, Tolley Limited

Panel · Access and Pricing · Hall L, Level 1

When Global Policy Agendas Collide – Evidence, Value, and Pricing Tensions at the Intersection of EU and US Reform

Oliver Staples · Aodan Tynan · Niklas Hedberg, TLV · Duane Schulthess, VitalTransformation BVBA

Panel · Access and Pricing · Hall E1, Level 0

Who Decides Which Covariates Matter? Aligning Regulatory and HTA Perspectives in Indirect Treatment Comparisons

Mikkel Oestergaard, Merck Sharp & Dohme International Service B.V. · Kate Ren, University of Sheffield · Anja Schiel, Norwegian Medicines Agency · Dominik Karres, European Medicines Agency

Talk · Access and Pricing · Connection Zone, Hall F Foyer, Level 0

The Accidental FX Trader: How United States MFN Pricing Reshapes Global Launch Strategy and Access

Diane Munch, Pfizer Inc · Neal Masia, EntityRisk, Inc. · Ramiro E Gilardino, Insights & Impact

Talk · AI · Theater 1, Hall X1-X4, Level -2

Let’s Get REAL: Real-World Evidence in Action

Denise Juliano, Premier Applied Sciences · Caroline Ryan, Teleflex · Lasair OCallaghan, Sanofi · Didier Morel, Becton Dickinson · Alexander de Groot, Intuitive Surgical

Talk · AI · Hall E2, Level 0

Advancing Evidence-Based Medicine with Generative AI

Jimmy Royer, Analysis Group, Montreal · Eric Q Wu, Analysis Group · Maxime Leroux, DMined Consulting Services, Montreal

Panel · Hall L, Level 1

AI in HEOR: Advancing Evidence Generation for Joint Clinical Assessment

Dalia Dawoud, Cytel · Manuel Cossio, Cytel · William Rawlinson, Estima Scientific · James Ryan, AstraZeneca

Workshop · Patient-Centered Evidence · Hall G1, Level -2

How Can HTA and Regulatory Guidelines and Reviews Strengthen the Case for More Patient Centered Evidence Creation?

Katja Rudell, Kielo Research · Dan Ollendorf, Institute for Clinical and Economic Review (ICER) · Joe Vandigo, Applied Patient Experience, A Reservoir Health Company

Panel · Hall K2, Level -2

ISPOR Strategic Dialogues: Integrated Evidence Generation Across the Product Lifecycle

Finn Børlum Kristensen, Danish Centre for Health Economics - University of Southern Denmark · Michael Berntgen, European Medicines Agency · Carlos Martin Saborido, Roche · Beate Wieseler, IQWiG · Maya Matthews, European Commission · Antonella M Cardone, Cancer Patients Europe

Talk · Access and Pricing · Hall F1, Level 0

One JCA, Many Decisions: Building an Evidence Strategy for Portability Across Europe

Martin Parkinson, Thermo Fisher Scientific · Carla Dias Barbosa, Thermo Fisher Scientific · Victoria F Paly, Takeda Oncology · Caoimhe T Rice, Thermo Fischer Scientific

Panel · Hall E1, Level 0

SMDM-ISPOR Joint Initiative in Health Decision Modelling Agentic AI for Transparent, Reproducible, and Trustworthy Decision Models

Uwe Siebert, UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health · Jag Chhatwal, Harvard Medical School / Massachusetts General Hospital · Beate Jahn, UMIT TIROL – University for Health Sciences and Technology · Beth Devine, University of York

Panel · Hall F2, Level 0

The Non-3G (GENEROUS, GLOBE, GUARD) Pricing Paradox: Navigating the "MFN Trap" Opportunities and Risk in Latin America, the Middle East, and Asia

Manuel Antonio Espinoza · Diego Guarin, ISPOR Latin America Consortium Chair · Mahendra K Rai, Trinity Lifesciences · Nadia Rashed Al Mazrouei, University of Sharjah

Talk · Connection Zone, Hall F Foyer, Level 0

From Subject-Matter Brilliance to Real Impact

Natalia Scherff, Natalia Scherff · Karina Hansen, NOVARTIS · Reg Waldeck

Talk · Access and Pricing · Theater 2, Hall X1-X4, Level -2

How Early Is Early Enough? Rethinking Evidence Planning for Today's Global Access Challenges

Priti Jhingran, Genesis Research Group

Talk · Real-World Evidence (RWE) · Theater 1, Hall X1-X4, Level -2

Spotlight on Joint Clinical Assessments: Learnings to Date, Looking Ahead at Rare Indications, and AI Applications to Enhance Evidence Generation

Jackie Vanderpuye-Orgle, PAREXEL

Panel · Patient-Centered Evidence · Hall L, Level 1

Are Patient Values Genuinely Shaping Value Assessment, or Do They Remain Acknowledged but Underutilized?

Ramiro E Gilardino, Insights & Impact · Dan Ollendorf, Institute for Clinical and Economic Review (ICER) · Chris Skedgel, Office of Health Economics · Antonella M Cardone, Cancer Patients Europe

Panel · Access and Pricing · Hall E2, Level 0

Beware (Non-Proportional) Hazard! Alternative Routes for Dealing with Time-Varying Treatment Effects in Evidence Synthesis for Health Technology Assessment (HTA) Decision Making

Keith R Abrams, University of Warwick · David Phillippo, University of Bristol · Rhiannon K Owen, Swansea University · Shannon Cope, Unpuzzle HEOR, VANCOUVER

Panel · Patient-Centered Evidence · Hall G1, Level -2

COAlescing the Oncology COA Strategy: A Provocative Look at Why Oncology COA Strategies Often Fail - and How to Fix Them

Konstantina Skaltsa, IQVIA · Bryan Bennett, Jazz Pharma · Lindsay Hughes, IQVIA · Flora Mulkey, Food and Drug Administration

Panel · Access and Pricing · Hall D, Level -2

First Wave, First Lessons: Multi-Stakeholder Insights from the initial Joint Clinical Assessments Under the European Regulation on Health Technology Assessment

Suzette Matthijsse, Lumanity · Anne Willemsen, Zorginstituut Nederland · James Ryan, AstraZeneca · Niklas Hedberg, TLV

Talk · Theater 2, Hall X1-X4, Level -2

Health Utility Measurement: EQ-5D Innovations and Broader Perspectives

Janine van Til, University of Twente

Workshop · Access and Pricing · Hall E1, Level 0

How Will the Most Favored Nation (MFN) Policy Influence Medicines Pricing and Access in Europe and How Should Policy Makers Respond?

Sean D Sullivan, University of Washington · IRIA ALVAREZ NOVOA IGLESIAS · Beth Woods, University of York

Workshop · Access and Pricing · Hall F2, Level 0

Reading Between the Endpoints: Translating Trials from Regulatory Estimands to HTA/JCA Decision Making

Miranda Cooper, AstraZeneca · Uwe Siebert, UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health · Antonia Morga, Astellas Pharma Ltd · Dominik Karres, European Medicines Agency

Panel · Real-World Evidence (RWE) · Hall K2, Level -2

Should Real-World Evidence Play a Role in Reimbursement Decisions on Decommissioning Health Technologies?

Tammy Wynne, Acumetis · Isabelle Durand-Zaleski · Maria-Magdalena Balp, Novartis Pharma AG · Linus Jönsson, Karolinska Insitutet

Talk · Theater 1, Hall X1-X4, Level -2

Tackling Societal Challenges Facing Public Health

Manuela Deidda, University of Glasgow

Panel · AI · Hall F1, Level 0

The Future of Causal Inference: How Large (or Small) Role Will AI Play?

Radek Wasiak, Adigens Health Limited · Miguel Hernan, Harvard T.H. Chan School of Public Health · Gorana Capkun · Michael Haft, Xplain Data

Talk · Access and Pricing · Theater 1, Hall X1-X4, Level -2

Preparing Orphan Medicinal Products for JCA: Strengthening the Evidence Package

Suzette Matthijsse, Lumanity · Miranda Cooper, AstraZeneca · Triona Zelesnik, Lumanity

Talk · Real-World Evidence (RWE) · Theater 2, Hall X1-X4, Level -2

Real-Time Intelligence: AI-Enabled Insights to Drive Evidence Strategy

Ryan Ahern, Truveta

Talk · Expanded Value Measures · Hall F1, Level 0

From HTA to Public Health: Rethinking Value in Obesity

Erin Johansson, Eli Lilly · Olivia Wu, University of Glasgow · Michal Pochopien, Clever-Access · Lieven Annemans, Ghent University

Panel · Hall G1, Level -2

From Policy to Practice: The Evolution of HEOR and Healthcare Decision-Making in China — Experiences, Insights, and Lessons Learned

Jing Wu, Tianjin University · Yue Yang · Wen Chen, School of Public Health, Fudan University · Tao Guo, The Guiding Center of Pharmaceuticals and Medical Service Pricing, Tendering and Purchasing, National

Panel · Hall E1, Level 0

From Value Assessment to Delivery Reality: Integrating HEOR and Health Systems Perspectives in Coverage Decisions for GLP-1 Therapies

Kelly Saldana, ISPOR · Sara Al Dallal · Sabry Hamza · Rania Abdelaziz, Health Insurance Organization

Panel · Patient-Centered Evidence · Hall L, Level 1

Informing Healthcare Investment Through a Patient-Centered Lens

Alan Balch, Patient Advocate Foundation and National Patient Advocate Foundation · Hayley Chapman, The Synergist, Oakville · Gunnar Esiason, RA Ventures · Brian O'Rourke, Independent, Ottawa · Julia Persson, Scita Health

Talk · Patient-Centered Evidence · Hall E2, Level 0

One Assessment, Many Decisions: The Future of Country-Level HTA After JCA

Ruairi O'Donnell, Cencora · Anne Willemsen, Zorginstituut Nederland · Neil Grubert, Neil Grubert Consulting · Anna Shopova, Amgen (Europe) GmbH · Antonella M Cardone, Cancer Patients Europe

Panel · Connection Zone, Hall F Foyer, Level 0

Shaping the Future of HEOR: A Special Preview of ISPOR's Updated Science Strategy

Laura Pizzi, ISPOR · Deborah A Marshall, University of Calgary, Calgary · Zsombor J Zrubka, Initium Zrt., Budapest · Peter Neumann, Tufts Medical Center

Panel · Hall F2, Level 0

The HEMA Debate: The Value Judgements Involved in Deciding How “Value” Is Measured: A Value in Health Forum

alistair mcguire · Nancy J Devlin, University of Melbourne · Darius Lakdawalla, University of Southern California · Mark Sculpher, University of York

Panel · Access and Pricing · Hall K2, Level -2

Updating HTA Methods in Central and Eastern Europe: Can National Guidelines Converge While Remaining Locally Relevant?

Maciej Niewada, ISPOR Poland Chapter · Magdalena Rdzanek, AOTMiT · Oresta Piniazhko, State Expert Center of the Ministry of Health of Ukraine · Tomáš Doležal, Value Outcomes s.r.o.

Panel · AI · Hall D, Level -2

Agentic AI Governance: How to Balance Innovation and Guidance

Amir Mehr, The Synthesis Company · Thomas Paulsson, Recordati Rare Diseases · Amanda Hansson Hedblom, Valid Insight (Bioscript Group), London · Michael J Merchant, NICE

Talk · Theater 1, Hall X1-X4, Level -2

Artificial Intelligence for Evidence Generation and Synthesis

Beate Jahn, UMIT TIROL – University for Health Sciences and Technology

Workshop · Real-World Evidence (RWE) · Hall E2, Level 0

Beyond “Using RWE”: What It Takes to Make Real-World Evidence Decision-Grade for HTA?

Mark Sculpher, University of York · Tina Wang, CIRS · Huajie Jin, King's College London · Xiaoning He, Tianjin University

Talk · Theater 2, Hall X1-X4, Level -2

Case Studies in Med Tech Evaluation

Abeer A Al Rabayah, King Hussein Cancer Center

Panel · Access and Pricing · Hall F1, Level 0

EU HTA System Readiness for Orphan Medicinal Products ahead of 13 January 2028

Alexander Natz, EUCOPE · Pierrick Rollet, Rare Diseases, Alexion · Niklas Hedberg, TLV · Matteo SCARABELLI, SERVIER · Antonella M Cardone, Cancer Patients Europe

Panel · Patient-Centered Evidence · Hall G1, Level -2

ICH E22 – General Considerations for Patient Preference Studies: Are We Ready to Move from Guidance to Practice?

Brett Hauber, Pfizer · Conny Berlin · Francesco Pignatti, European Medicines Agency · Juan M Gonzalez, Duke Clinical Research Institute

Workshop · Expanded Value Measures · Hall K2, Level -2

Integrating Environmental Sustainability into HTA: Global Policy Archetypes and Future Directions for Access Decision-Making

Anke-Peggy Holtorf, Health Outcomes Strategies, GmbH · Sandro Gsteiger, Roche · Fiona Adshead, Sustainable Healthcare Coalition · Stuart Mealing, York Health Economics Consortium

Workshop · Access and Pricing · Hall F2, Level 0

Joint Clinical Assessment (JCA) and Pan-European Solidarity-Based Reimbursement Model (PANSOL) - Is Collaborative Assessment Meeting the Needs of EU Member States?

Lieven Annemans, Ghent University · Mark Parker · Krzysztof M Landa, Watch Health Care Foundation · Tanja Novakovic

Workshop · Hall E1, Level 0

Mixture Cure Models: Do They Create More Issues Than They are Trying to Solve?

Seán Conlon · Gianluca Baio, University College London · Irina Proskorovsky, Thermo Fisher Scientific · Rhiannon K Owen, Swansea University

Panel · Expanded Value Measures · Hall L, Level 1

Whole Health at Risk: Does EU Joint Clinical Assessment Conflict with Europe’s Antimicrobial Resistance Ambitions?

Matthias Hofer, The Office of Health Economics · Anja Schiel, Norwegian Medicines Agency · Libby Hamson, GSK · Patrick K Hopkinson, Independent Consultant

Networking

ISPOR Welcome Reception

Keynote · Hall A, Level 2

Plenary Session 2: Presidential Address, and Keynote Speaker

Beth Devine, University of York · Ricardo Baptista Leite, HealthAI

Panel · Expanded Value Measures · Hall A, Level 2

Plenary Session 2: We Optimize Treatments—But How Do We Optimize the System?

Rasmus Gjesing · Ricardo Baptista Leite, HealthAI · Jakub Dvorácek, Pluxee · Carole Longson, University of Manchester

Panel · Real-World Evidence (RWE) · Hall K2, Level -2

Beyond the Trial: Real-World Evidence and Lifecycle Evidence Generation in NICE Existing-Use HealthTech Assessments

Dawn Lee, University of Exeter PenTAG · Michael Kolovetsios, Johnson & Johnson MedTech · Stacey Chang-Douglass, Insira (formerly Clarivate LS&H) · Anastasia Chalkidou, NICE

Panel · Real-World Evidence (RWE) · Hall F1, Level 0

Bridging China and Europe: When Is China-Generated Evidence Fit for European HTA?

Ruslan Horblyuk, Aesara · Jing Wu, Tianjin University · Huajie Jin, King's College London · Ross A Selby, Italfarmaco SpA

Panel · AI · Hall E1, Level 0

Can Agentic AI Deliver HTA-Ready Health Economic Models? Governance, Validation, and Trust

Andrew Briggs, London School of Hygiene & Tropical Medicine · Andre Verhoek, AstraZeneca · Jag Chhatwal, Harvard Medical School / Massachusetts General Hospital · Xiaoyan Wang, Tulane University

Panel · Access and Pricing · Hall D, Level -2

Convergence and the Transatlantic Bargain: US Pricing Reform, the EU Pharma Package, and What Either Means for Innovation and Access

Indranil Bagchi, GSK US · Ferenc Marofka, European Commission · Sean D Sullivan, University of Washington · Lotte Steuten, Office of Health Economics

Workshop · AI · Hall E2, Level 0

Embracing the Opportunity of AI in Economic Modelling Responsibly Through Agentic Workflows and Guardrails

Beth Devine, University of York · Timothy Reason, Estima Scientific · Liza Zasukhina, MSD · Dan Ollendorf, Institute for Clinical and Economic Review (ICER)

Talk · Theater 1, Hall X1-X4, Level -2

Generating Decision-Ready Evidence for HTA and JCA

Fatima Salih, NICE

Panel · Patient-Centered Evidence · Hall G1, Level -2

Patient Engagement in Economic Modelling: Bridging the Gap Between What’s Measured and What Matters

Neil Hawkins, University of Glasgow · Ariel Yuhan Y Ong, Moorfields Eye Hospital NHS Foundation Trust · Noemi Muszbek, Visible Analytics Ltd · Matthew Selby, Ocular Melanoma UK

Talk · Theater 2, Hall X1-X4, Level -2

Patient Preferences in Healthcare Decision-Making: Global Insights from Discrete Choice and Preference Studies

Sam Llewellyn, Vitaccess

Panel · AI · Hall F2, Level 0

Responsible AI in HTA - Introducing the NICE AI Methods Framework

Mitch Higashi, ISPOR · Raphael Sonabend-Friend, NICE · Sven L Klijn, Bristol Myers Squibb · Yan Teck Ho, Ministry of Health · James Fotheringham, University of Sheffield

Panel · Expanded Value Measures · Hall L, Level 1

VBHC x HEOR: From Shared Principles to Better Decisions - Are We There Yet?

William V Padula, University of Southern California · Jens Grueger, CHOICE Institute, University of Washington · Borja Garcia-Lorenzo, Biosistemak Institute · Mariska Q Hackert

Talk · AI · Connection Zone, Hall F Foyer, Level 0

The Next Generation of HEOR: Career Pathways in an AI-Augmented Field

Ghayath Janoudi, Loon, Ottawa · Anggie Wiyani, Novartis · Erika Wissinger, Cencora · Vandana Ayyar Gupta, NICE

Talk · Real-World Evidence (RWE) · Theater 1, Hall X1-X4, Level -2

From Narrative to Evidence: How NLP-Extracted Clinical Facts Strengthen Real-World Research

Jeffrey Brown, TriNetX, LLC

Talk · Patient-Centered Evidence · Theater 2, Hall X1-X4, Level -2

Patient Experience Data in Health Economics and Outcomes Research – Challenges, Solutions and Strategic Value

Gavin Taylor-Stokes, Adelphi Real World · Danielle Riley, Adelphi Values PROVE · Helena Bradley, Adelphi Values PCO

Panel · Hall F2, Level 0

Are New EU Policies Really Going to Improve RWD Availability to Inform Access Decisions?

Sandipan Bhattacharjee, Bayer U.S. LLC · Niklas Hedberg, TLV · Alexander Natz, EUCOPE

Talk · Expanded Value Measures · Hall E2, Level 0

Beyond Healthcare Costs: Valuing Obesity Treatment for Patients, Workforces, and Society

Francesca Fiorentino, IQVIA · Hanène Samouda, LASO (Luxembourg Association of People Living with Obesity) · Johan Fagerudd, Pihlajalinna · Robert King, LCP Health, Lane Clark & Peacock LLP · Aparajita Tyagi, Novo Nordisk A/S

Panel · Hall E1, Level 0

Beyond Pricing: How HTA Informs Health System Decisions Worldwide

Jessica Daw, Sentara Health Plans · Claire Telford, Pfizer · Joseph Mfutso-Bengo, Kamuzu University of Health Sciences · Fatimah Alyami, Center for Health Technology Assessment, Center for National Health Insurance · Sudha Kutty, Canada's Drug Agency, Toronto

Panel · Patient-Centered Evidence · Hall G1, Level -2

From Experience to Evidence: Building Patients’ Capabilities for Patient Experience Data (PED) in HTA

Maria Dutarte, European Patients’ Academy on Therapeutic Innovation (EUPATI) · Anke-Peggy Holtorf, Health Outcomes Strategies, GmbH · Jose Diaz, BMS · Alan Balch, Patient Advocate Foundation and National Patient Advocate Foundation · claas roehl

Panel · Hall L, Level 1

From Principles to Practice: Preliminary Good Practice Recommendations from the Joint ISPOR-SMDM Model Validation II Task Force

Salah Ghabri, French National Authority for Health (HAS) · Beate Jahn, UMIT TIROL – University for Health Sciences and Technology · Isaac Corro Ramos, Erasmus University · Mafalda Ramos, Th(is)²Modeling

Panel · Hall K2, Level -2

Opportunity Cost, or Opportunity Lost? Sacred Principle, Functional Fiction, or Evolving Concept in HTA?

Laura Pizzi, ISPOR · Dan Ollendorf, Institute for Clinical and Economic Review (ICER) · Lotte Steuten, Office of Health Economics · Chris Sampson, Tertium Research

Talk · Connection Zone, Hall F Foyer, Level 0

Finding and Exploring HTA Methods: An Interactive Demonstration of the SUSTAIN Methods Observatory

Wim Goettsch, Zorginstituut Nederland · Saif Elayan, Utrecht University · Nicole Mittmann, Canada's Drug Agency, Toronto

Talk · AI · Theater 1, Hall X1-X4, Level -2

From Research Question to Rigorous Evidence: A Subject-Matter Expert Agentic AI Workflow for HCRU Studies

Katie Mues, Datavant · Ornela Xhelili, Datavant

Talk · Theater 2, Hall X1-X4, Level -2

AI Applications in Health Technology Assessment

Salah Ghabri, French National Authority for Health (HAS)

Panel · Expanded Value Measures · Hall K2, Level -2

Are HTA and Health Funding Systems Failing to Incentivise Investment in Disease Prevention?

Eleanor Thurtle, Costello Medical · Grace Hampson, Office of Health Economics · James Jarrett, Gilead Sciences Inc · Rosanna Tarricone, Bocconi University

Panel · Real-World Evidence (RWE) · Hall F1, Level 0

Beyond the Chinese Market: How China-Generated Evidence is Reshaping Global HTA, Access, and Reimbursement Decisions

Yu Fang · Lizheng Shi, Tulane University School of Public Health and Tropical Medicine · Minghuan Jiang, Xi'an Jiaotong University · Le Gao, Xi'an JiaoTong University

Panel · Access and Pricing · Hall E1, Level 0

Delay or Prepare? Navigating EU HTA in the Era of MFN-Driven Launch Uncertainty

Eric C Faulkner, Passage Health Associates · Joerg Ruof · Jon D Campbell, National Pharmaceutical Council · Gregory Daniel, Eli Lilly & Co. Ltd.

Workshop · Patient-Centered Evidence · Hall G1, Level -2

Developing Qualitative Vignettes to Explore Patient Perspectives of Meaningful Change in Clinical Outcomes Assessment: AI-based and Manual Methodological Applications

Helen Kitchen, Clarivate · Piper Fromy · Catherine Bottomley, Clarivate Analytics · Natalie Aldhouse

Panel · Patient-Centered Evidence · Hall E2, Level 0

Methods for Health State Utility Estimation: Task Framing, Current Practice, and Future Directions in HTA

Matthijs M Versteegh, Huygens & Versteegh · Dawn Lee, University of Exeter PenTAG · Matthew Franklin, SCHARR, University of Sheffield · Andrew Lloyd, Acaster Lloyd · Tianhao Chen, The University of Sheffield

Workshop · Hall L, Level 1

Modern Synthesis Methods for Estimating Subgroup-Specific Treatment Effects

Antonio Remiro-Azócar · Jeroen P Jansen, University of California, San Francisco; Precision AQ · Renato Panaro · Harlan Campbell, Precision AQ, Rossland

Talk · Theater 1, Hall X1-X4, Level -2

New Forces Shaping Global Pricing

Hussain A Al-Omar, College of Pharmacy, King Saud University

Panel · Access and Pricing · Hall D, Level -2

Parallel Joint Scientific Consultations Under the EU HTA Regulation: What Have We Learned from the First Procedures?

Mihai Rotaru, EFPIA · Karina Hansen, NOVARTIS · Stephanie Said · Michael Berntgen, European Medicines Agency

Panel · AI · Hall F2, Level 0

Train the Economist or Hire the Engineer? The Future of Expertise in AI-Native HEOR

Ramiro E Gilardino, Insights & Impact · J. Jaime Caro, Thermo Fisher Scientific · Manuel Cossio, Cytel · Mitch Higashi, ISPOR

Talk · Patient-Centered Evidence · Theater 2, Hall X1-X4, Level -2

From Routine Care to Decision-Grade Evidence: Scaling Pragmatic Trials Across Health Systems

Bruce Feinberg, Cardinal Health · Nicholas Lazarou, Cardinal Health

Panel · Hall K2, Level -2

From Evidence to Enterprise Value: Communicating HEOR's Value to Executive Leadership

Jan E Hansen, Sanofi · Craig Roberts, Merck · Russ Montgomery, GSK US · Clark Paramore, Biogen

Panel · Hall E1, Level 0

Generative AI for Systematic Literature Reviews: ISPOR Good Practices Task Force Findings

Dalia Dawoud, Cytel · Jag Chhatwal, Harvard Medical School / Massachusetts General Hospital · Raphael Sonabend-Friend, NICE · Sven L Klijn, Bristol Myers Squibb

Panel · Connection Zone, Hall F Foyer, Level 0

Inside the EMA: A Bird's-Eye View of Europe's Medicines Regulator

Laura Pizzi, ISPOR · Michael Berntgen, European Medicines Agency · Francesco Pignatti, European Medicines Agency · Dominik Karres, European Medicines Agency

Panel · Hall F2, Level 0

Shaping the Global Research and Policy Agenda in HEOR in the Next Decade: A Value in Health Regional Issues Forum

Manuel Antonio Espinoza · Lotte Steuten, Office of Health Economics · Rafael Pinedo-Villanueva, University of Oxford · Jing Wu, Tianjin University

Panel · Hall L, Level 1

Using Patient Centered Digital Endpoints to Measure Whole Health

Annette Champion, Healthcare Research Insights, Inc · Anita D Burrell, Anita Burrell Consulting LLC · Anke-Peggy Holtorf, Health Outcomes Strategies, GmbH · Ward Servaes, Cascador/moveUP

Panel · Expanded Value Measures · Hall G1, Level -2

Vaccination Coverage an opportunity lost: Are European Health Systems Leaving Health Benefits on the Table?

Cornelis Boersma, Health-Ecore · Adina Turcu-Stiolica, University Of Medicine And Pharmacy Of Craiova · Aleksandra Grozdanova, University Ss. Cyril and Methodius, Faculty of Pharmacy · Tarik Catic

Talk · Expanded Value Measures · Hall E2, Level 0

Whole Health and HTA: Ready and Willing, or Not So Much? Rethinking Measurement in Health Technology Assessment

Lisette Nientker, OPEN Health · Ben A van Hout, OPEN Health · Shruti Pandey, OPEN Health · Malina Müller, WifOR Institute · James Ryan, AstraZeneca

Workshop · Patient-Centered Evidence · Hall K2, Level -2

Accounting for Preference Heterogeneity in Stated Choice Data: From Good-Practice Methods to Decision-Relevant Interpretation

Deborah A Marshall, University of Calgary, Calgary · Francesco Pignatti, European Medicines Agency · Sebastian Heidenreich, Thermo Fisher Scientific · Axel C Mühlbacher, HS Neubrandenburg

Talk · Theater 1, Hall X1-X4, Level -2

Addressing the Challenges in Rare Disease Methods

Matt Griffiths, Costello Medical

Talk · Theater 1, Hall X1-X4, Level -2

Advances in Decision Analytics and Economic Evaluation

Imre Boncz, University of Pécs

Panel · AI · Hall G1, Level -2

AI-Assisted Health Economic Modeling: Balancing Human-AI Workflows to Ensure Efficient, Robust, Transparent & Compliant Decision Making for HTAs

Ray Gani, PharmaQuant · Ronan Mahon, University of Galway · Vandana Ayyar Gupta, NICE · Peter Quon, Regeneron

Panel · Expanded Value Measures · Hall F1, Level 0

Bridging the Gap Between Broader Value Frameworks and Research-Ready Decision-Making

Malina Müller, WifOR Institute · Petra Došenovic Bonca · Valentina Prevolnik Rupel · Wim Goettsch, Zorginstituut Nederland

Panel · Access and Pricing · Hall D, Level -2

Could a Higher Willingness-to-Pay for 'Innovative' Therapies in Cost Effectiveness HTAs Help Enable Europe to Retain R&D and Manufacturing?

Lieven Annemans, Ghent University · Natalie Bennett, Novartis Pharmaceuticals UK Limited · Mark Sculpher, University of York · Lotte Steuten, Office of Health Economics

Workshop · Real-World Evidence (RWE) · Hall E2, Level 0

From Evidence to Access in Asia: Lessons on RWE and Lifecycle HTA for Sustainable Reimbursement

Feng Xie, McMaster University, Hamilton, ON · Hae Sun Suh, Kyung Hee University · Huang-tz Ou, National Cheng Kung University · Shitong Xie, Tianjin University

Panel · Real-World Evidence (RWE) · Hall E1, Level 0

How to Unlock the Usage of Real-World Data for Medical Devices in Health Technology Assessments?

Frederique Debroucker, Medtronic · Jana Boleckova, Edwards Lifesciences Sàrl · Daniel Prieto-Alhambra · Anastasia Chalkidou, NICE

Panel · AI · Hall L, Level 1

Impact of Agentic AI on Redefining Productivity in HEOR: From Deliverables to Decision Impact

Uwe Siebert, UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health · Jag Chhatwal, Harvard Medical School / Massachusetts General Hospital · Turgay Ayer, Value Analytics Labs · Ipek Ozer Stillman, Takeda

Panel · Access and Pricing · Hall F2, Level 0

Most Favored Nation Pricing: Will International Price Alignment Improve Affordability or Restrict Access to Innovation? Insights from Central and Eastern Europe

Roman Casciano, Certara USA Inc. · Marcin Czech, Institute of Mother and Child · Michal Worotynski, Ewopharma · Adam Parnaby

Workshop · Real-World Evidence (RWE) · Hall E2, Level 0

Biases that Generate Immortal Time: A Structural Diagnosis and Practical Solutions for HTA Submissions

Miguel Hernan, Harvard T.H. Chan School of Public Health · Xabier Garcia de Albeniz, Adigens Health Limited · Thibaut Sanglier, F.Hoffmann-La Roche · Julia Vila, RTI Health Solutions

Panel · Expanded Value Measures · Hall G1, Level -2

Can We STEDI the Course? Antimicrobial Value Assessment at a Crossroads

Laith Yakob, Adelphi Values PROVE · Edward I Broughton, Pfizer · Grace Hampson, Office of Health Economics · Entela Xoxi, Independent Consultant

Workshop · Patient-Centered Evidence · Hall L, Level 1

Children or Parents - Whose Preferences Matter? That Depends on the Decision Making Context

Kerrie-Anne Ho, UCB · Nancy J Devlin, University of Melbourne · Deborah A Marshall, University of Calgary, Calgary

Panel · Real-World Evidence (RWE) · Hall D, Level -2

From Static to Dynamic Value: Can Living HTA and AI Reshape the Innovation Cycle?

Esther Nzenza, Acumetis, Clerkenwell · Olivia Wu, University of Glasgow · Nicholas Adlard, Novartis Pharma · Sabine Vogler, Gesundheit Osterreich GmbH

Panel · Access and Pricing · Hall E1, Level 0

How Should Evidence be Assessed in Rare Diseases?

Karen Facey, Universities of Utrecht and Edinburgh and RWE4Decisions · J. Jaime Caro, Thermo Fisher Scientific · Sean Tunis, Tufts Center for the Evaluation of Value and Risk in Health

Panel · Expanded Value Measures · Hall K2, Level -2

No Longer Inevitable: Avoidable Hospitalizations As a Catalyst for Health System Transformation

Andreas Heddini, AstraZeneca · Penilla Gunther · Richard Russell · Kelly Saldana, ISPOR

Panel · Access and Pricing · Hall F2, Level 0

Preparing CEE Countries for JCA: Aligning European HTA Standards with National Access Decisions

Magda Chatzikou, Pharmecons Easy Access · Tarang Sharma, WHO · Jacek Walczak · Boryana Ivanova

Panel · Access and Pricing · Hall F1, Level 0

Three Pathways from HTA to Access in China, the UAE, and South Africa: Price Negotiation, Value-Based Decision-Making, and Equity-Driven Priority-Setting

Nuriya Musina, Accesstra Health Institute · Kefah Ali Alqawasmeh, AUH · Jani Mueller, Jani Mueller · Yi Yang

Talk · Theater 1, Hall X1-X4, Level -2

Beyond the Kaplan–Meier Curve: Advances in Survival Analysis

Martin Scott, Numerus

Talk · Theater 2, Hall X1-X4, Level -2

Navigating PICOs in the Era of JCA

Steffen Wahler, St. Bernward

Panel · Expanded Value Measures · Hall D, Level -2

Bringing Environmental Impact into Healthcare Value Assessment: An ISPOR Health Science and Policy Council Spotlight Session

Zoltán Kaló, National Health Insurance Fund; Center for Health Technology Assessment, Semmelweis University · Erik van Raaij, Erasmus University Rotterdam · Céline Fernandez, SANOFI GROUP · Joukje de Vries, CE Delft

Panel · Access and Pricing · Hall L, Level 1

Can CEE Healthcare Systems Afford Innovation Without Reforming Procurement and Financing Models?

Izabela Pieniazek, Certara · Joanna Lis, Polskie Towarzystwo Farmakoekonomiczne PTFE · Krzysztof M Landa, Watch Health Care Foundation · Elena Chitan, Nicolae Testemitanu State University of Medicine and Pharmacy

Panel · Hall F1, Level 0

From Framework to Practice: Piloting a Harmonized EU Approach to Early Feasibility Studies to Shape the Future Medical Device Regulatory Framework

Giuditta Callea, SDA Bocconi School of Management · Alexandra Poulsson, Norwegian Institute of Public Health · Marta Bragagnolo, Global Heart Hub · Fanny van der Loo, Edwards Lifesciences

Panel · Access and Pricing · Hall E1, Level 0

From National HTA to Joint Clinical Assessment: Exploring Similarities and Differences in Comparator and Outcome Selection Across Six European Health Technology Assessment Agencies

Anne Willemsen, Zorginstituut Nederland · Roisin Adams · Keltoum Merroune, Haute Autorité de Santé · Stephanie Said

Talk · Theater 1, Hall X1-X4, Level -2

From PICO to Practice: Advancing Evidence Synthesis

Jeroen P Jansen, University of California, San Francisco; Precision AQ

Panel · Access and Pricing · Hall F2, Level 0

HTA as Enabler, Not Blocker: Which Redesign Should Come First to Support Procurement Decisions in Smaller European Health Systems?

Lou Garrison, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute · Jorge Mestre-Ferrandiz, Profesor Asociado · Dávid Dankó, Ideas & Solutions · Olivier Wong, MEDI-QUALITE OMEGA

Panel · AI · Hall K2, Level -2

Issues in Evaluating AI-Enabled Healthcare

Seamus Kent, Erasmus University Rotterdam · Anastasia Chalkidou, NICE · Blythe Adamson, Doctronic · Lena Bertozzi, Pomelo Care

Talk · Theater 2, Hall X1-X4, Level -2

Novel Value Elements and Approaches in HTA

Gihan H Elsisi, American University

Panel · Patient-Centered Evidence · Hall G1, Level -2

Small Sample, Big Decisions: Patient Preference Data for Regulatory and Payer Uses in Rare Diseases

Tommi Tervonen, Kielo Research · Kerrie-Anne Ho, UCB · Eric Low, Eric Low Consulting · Francesco Pignatti, European Medicines Agency

Panel · Access and Pricing · Hall E2, Level 0

The Triple Challenge: How Do Global Pricing Dynamics, with US MFN Policy, China’s Rise, and European Policies Converge and Impact European Competitiveness?

Casper Paardekooper, Cencora · Neil Grubert, Neil Grubert Consulting · Eelko den Breejen, Pfizer (Global) · Ferenc Marofka, European Commission

Keynote · Hall A, Level 2

Plenary Session 3: Closing Reflections and the Scientific Future of HEOR

Rob Abbott, ISPOR · Laura Pizzi, ISPOR · Kelly Saldana, ISPOR

Panel · AI · Hall A, Level 2

Plenary Session 3: Fit for Purpose: What HEOR Evidence Must Become

Malina Müller, WifOR Institute · Nick Guldemond, Leiden University Medical Center · Marie Gerstrøm Kristiansen, Amgros · Nirosha Lederer, AstraZeneca